The Ministry of Health of the Russian Federation has officially registered Arcerix (goflikicept), a drug developed by the R-Pharm group of companies. This pioneering medication is the first of its kind and currently stands as the sole treatment in Russia for targeted therapy of idiopathic recurrent pericarditis.
Goflikicept is a groundbreaking protein medication that neutralizes the cytokine interleukin-1β (IL-1), a pivotal factor in the progression of Mediterranean fever.
“The drug was developed from scratch in the R-Pharm laboratories and will be produced in Russia at the facilities of the group of companies. Arcerix is under patent protection in 24 countries,” the press service of the Group of Companies emphasized.
